Pluristem Therapeutics (PSTI) 2.91 $PSTI
NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST
VCEL: 3.71 (-0.01), PSTI: 2.91 (+0.01), NBS: 3.78 (+0.14), GSK: 47.94 (+1.99), IMUC: 0.54 (-0.03), KITE: 62.59 (+0.82), BAX: 70.39 (+0.31), ONCE: 46.25 (+0.07), JUNO: 40.52 (+0.18), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)
German Researchers Verify Positive, System-Wide Effect Of Pluristem's PLX Cell Therapy
Sharon di Stefano - Seeking Alpha - Wed Feb 11, 3:31PM CST
Pluristem Therapeutics Inc. (NASDAQ: PSTI ), maker of cell therapy for a wide variety of diseases, recently announced 12-month results from Phase I/II studies with its PLX-PAD off-the-shelf treatment for people who had undergone total hip...
PSTI: 2.91 (+0.01), CYTX: 0.47 (unch), STEM: 1.09 (-0.01), ATHX: 2.12 (unch), CUR: 3.41 (+0.13), CELG: 115.88 (+0.16)
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 2.98 (unch), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), MYGN: 34.03 (+0.40), PSTI: 2.91 (+0.01), PFE: 34.64 (-0.23), XON: 39.30 (+1.05), TKMR: 21.45 (-0.22), ASPX: 65.76 (+2.76), MNKD: 7.00 (+0.02), HSP: 87.35 (unch), ZTS: 45.46 (-0.33), ANTM: 141.05 (-0.95), WMGI: 25.68 (+0.17), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), THOR: 40.01 (+0.54), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
Coronary Artery Disease Therapeutics Pipeline Market H1 2015 Research Report Available at RnRMarketResearch.com
PRWeb - Thu Feb 05, 7:31AM CST
The report "Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease). Coronary artery disease (Ischemic Heart Disease) is the most common type of heart disease. Coronary artery disease is the tightening or blockage of the coronary arteries. A severe adequate blockage may cause a heart attack. Coronary artery disease (Ischemic Heart Disease) is the foremost cause of death in US, UK and globally. Most ischaemic heart disease is caused by atherosclerosis. However there are a number of risk factors.
CRME: 9.76 (-0.14), GILD: 101.90 (+1.10), PSTI: 2.91 (+0.01), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), EGRX: 20.98 (+1.45), BMY: 60.04 (+0.56), RGDO: 1.17 (+0.02)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 11:47AM CST
SD: 2.09 (+0.14), RAVE: 13.57 (+0.28), SPPR: 1.63 (-0.17), PSTI: 2.91 (+0.01), ONTX: 2.27 (-0.02), LMNX: 15.45 (+0.02), NBG: 1.61 (+0.18), ARDX: 17.14 (+0.71), CSIQ: 28.84 (-0.30), LFVN: 1.11 (-0.02), XNPT: 6.69 (-0.21), GBR: 1.48 (-0.10), GENE: 8.04 (+1.90), RCII: 30.49 (+0.92), PWE: 2.45 (+0.02), PSTR: 4.63 (+0.14), SSYS: 67.16 (-0.34), ODP: 9.59 (-0.02), ENRJ: 2.81 (+0.06)
Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure
M2 - Tue Feb 03, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/lb556t/regenerative) has announced the addition of the "Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure" report to their offering. Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets, approaches and biology are discovered. Improved health care, nutrition and preventive medicine in the last few decades have all helped in increasing life expectancy WW. However, this has not translated in any reduction in the incidences or prevalence of chronic or critical illnesses! On the contrary, the incidence of chronic diseases like diabetes, obesity, arthritis etc. as well as cancer and the maladies associated with aging (dementia, Alzheimer's etc.) are on the rise. Consequently the pharma industry continues to grow and is projected to achieve sales in excess of the trillion dollar mark by 2020. By the next decade, one field which is poised to bring a paradigm change in the way diseases are treated is the Stem cell therapy/Regenerative Medicine space. The number of companies and products in the clinic has reached a critical mass, warranting a close watch by those interested in keeping pace with the development of new medicines. This report describes the key growth drivers and reasons for why this sector is poised for the "golden dawn" and forecasts that in the coming years, the translation of stem cell research to the clinic and market and Stem Cell Technologies Will Begin to Break Through by 2017. Key Topics Covered: 1. Executive summary 2. Introduction 3. Tough Choice- Autologous vs. Allogenic " Therapies 4. Regulatory Scenario 5. Marketed Cell based/Stem Cell Products 6. Progress and Challenges 7. Merger and Acquisition- Gaining Momentum in Regenerative Space 8. Progress in Specific Therapy Areas Companies Mentioned - CESCA Therapeutics Inc. [KOOL] - JCR Pharmaceuticals [4552:JP] - Japan Tissue Engineering Co., Ltd [7774:JP] - Medipost Co. Ltd [078160:KS] - Mesoblast Ltd [MSB:AU] - OCATA Therapeutics Inc. [OCAT] - Orgenesis [ORGS] - Pluristem Therapeutics Inc [PSTI:IT] - TiGenix NV [ TIG:BB] For more information visit http://www.researchandmarkets.com/research/lb...generative
KOOL: 0.88 (-0.14), PSTI: 2.91 (+0.01)
Market Maker Surveillance Report. TBIO, PSTI, STRI, DWTI, HART, ARDX, Losing Stocks With Lowest Price Friction For Monday, February 2nd 2015
M2 - Tue Feb 03, 3:14AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 5214 companies with "abnormal" market making, 3994 companies with positive Friction Factors and 2396 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Monday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Transgenomic Inc (OTC:TBIO), Pluristem Therapeutics Inc (NASDAQ
STI), STR Holdings Inc New (NYSE:STRI), (NYSE
WTI), (NASDAQ:HART), (NASDAQ:ARDX). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
PSTI: 2.91 (+0.01), TBIO: 2.91 (+0.01), HART: 2.92 (+0.34), ARDX: 17.14 (+0.71), STRI: 1.65 (+0.04), DWTI: 95.90 (-7.40)
Pluristem Therapeutics: A Biotech Scam Promoted By A Bucket Shop
Probio Invest - at Seeking Alpha - Mon Feb 02, 3:37PM CST
CVM: 0.84 (-0.01), PSTI: 2.91 (+0.01), ORMP: 4.58 (+0.16)
Pluristem reports results from 20-patient study
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 9:54AM CST
PSTI: 2.91 (+0.01)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 8:12AM CST
BGMD: 0.88 (unch), SD: 2.09 (+0.14), FRO: 2.96 (+0.07), CAMT: 3.08 (+0.09), PWE: 2.45 (+0.02), HIHO: 3.30 (-0.17), PSTI: 2.91 (+0.01), ZGNX: 1.43 (+0.05), NBG: 1.61 (+0.18), SDRL: 12.32 (-0.70), GURE: 1.64 (-0.04)
Pluristem price-stoking analyst report questioned
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 6:37AM CST
PSTI: 2.91 (+0.01)
Pluristem Announces Significant New Finding From Its Phase I/II Muscle Injury Trial and Excellent Safety Profile for PLX-PAD Cells at Twelve Months
GlobeNewswire - Mon Feb 02, 1:45AM CST
Pluristem Therapeutics Inc. (Nasdaq STI) (TASE STI), a leading developer of placenta-based cell therapies, announced an important new finding from its Phase I/II clinical trial of PLacental eXpanded (PLX-PAD) cells in the treatment of muscle injury after total hip arthroplasty (THA). Data showed that six months after surgery the magnitude of improvement in muscle force of the contralateral (non-operated) gluteal muscle was approximately 40 times larger in patients treated with 150 million PLX-PAD cells than in those who received placebo, and the difference was statistically significant (19.4 vs 0.5 Nm, p=0.0114). Patients treated with 300 million PLX-PAD cells also showed a larger increase in muscle force than patients injected with placebo (9.48 vs 0.46 Nm, p=0.227). Pluristem further announced positive twelve-month safety data from the trial. These findings follow the January 21, 2014 announcement that the study had met its primary efficacy and safety endpoints. The primary efficacy finding was the change in maximal voluntary isometric contraction force of the gluteal muscle in the operated leg at six months after total hip replacement. There was a large and statistically significant improvement in patients who were injected with 150 million cells versus those who received placebo (31.1 vs 5.4 Nm, p=0.0067).
PSTI: 2.91 (+0.01)
Nasdaq stocks posting largest volume increases
AP - Thu Jan 29, 5:14PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
BELFB: 23.44 (+0.60), BELFA: 19.90 (-0.40), PSTI: 2.91 (+0.01), APPY: 0.45 (-0.01), NVC.TO: 11.27 (-0.23), GEVO: 0.23 (+0.03), PSTB: 6.94 (+0.04), OVLY: 10.65 (-0.05), PFMT: 6.02 (-0.02), BWINB: 23.41 (+0.01), AMIC: 10.75 (-0.10), APRI: 1.84 (-0.08), BWINA: 23.45 (-0.79), INOD: 2.78 (-0.02), XNCR: 15.47 (-0.22), FBSS: 17.59 (-0.11), NVCN: 9.08 (-0.17)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 8:12AM CST
CRMD: 3.27 (+0.02), FRO: 2.96 (+0.07), PSTI: 2.91 (+0.01), SILC: 46.99 (+0.90), VVUS: 2.68 (+0.13), NBG: 1.61 (+0.18), APPY: 0.45 (-0.01), CLB: 112.18 (+3.65), YHOO: 44.42 (+0.50), RCL: 75.56 (-1.19), COH: 39.85 (+0.64), QCOM: 70.88 (+0.49), IRE: 14.54 (+0.81), VGGL: 1.77 (-0.08), KATE: 33.89 (+0.05), XNCR: 15.47 (-0.22), MLNX: 46.35 (+1.47), FTNT: 33.23 (+0.25), BABA: 89.05 (+1.95)
Pluristem Therapeutics (PSTI) in Focus: Stock Surges 20.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 7:37AM CST
Pluristem Therapeutics, Inc. (PSTI) was a big mover last session, as the company saw its shares rise more than 20% on the day.
PSTI: 2.91 (+0.01), ALXN: 182.29 (+6.02)
Pluristem surges on bullish research report
Seeking Alpha - at Seeking Alpha - Wed Jan 28, 8:02AM CST
PSTI: 2.91 (+0.01)
Updated Coverage Report Focuses on Pluristem Therapeutics
Marketwired - Tue Jan 27, 3:00AM CST
Pluristem Therapuetics (NASDAQ: PSTI) is the subject of an updated coverage report by Acceleron Equity Research, a stock market research firm focused on emerging companies and technologies.
PSTI: 2.91 (+0.01)
NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST
VCEL: 3.71 (-0.01), PSTI: 2.91 (+0.01), NBS: 3.78 (+0.14), GSK: 47.94 (+1.99), IMUC: 0.54 (-0.03), KITE: 62.59 (+0.82), BAX: 70.39 (+0.31), ONCE: 46.25 (+0.07), JUNO: 40.52 (+0.18), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)
German Researchers Verify Positive, System-Wide Effect Of Pluristem's PLX Cell Therapy
Sharon di Stefano - Seeking Alpha - Wed Feb 11, 3:31PM CST
Pluristem Therapeutics Inc. (NASDAQ: PSTI ), maker of cell therapy for a wide variety of diseases, recently announced 12-month results from Phase I/II studies with its PLX-PAD off-the-shelf treatment for people who had undergone total hip...
PSTI: 2.91 (+0.01), CYTX: 0.47 (unch), STEM: 1.09 (-0.01), ATHX: 2.12 (unch), CUR: 3.41 (+0.13), CELG: 115.88 (+0.16)
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 2.98 (unch), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), MYGN: 34.03 (+0.40), PSTI: 2.91 (+0.01), PFE: 34.64 (-0.23), XON: 39.30 (+1.05), TKMR: 21.45 (-0.22), ASPX: 65.76 (+2.76), MNKD: 7.00 (+0.02), HSP: 87.35 (unch), ZTS: 45.46 (-0.33), ANTM: 141.05 (-0.95), WMGI: 25.68 (+0.17), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), THOR: 40.01 (+0.54), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
Coronary Artery Disease Therapeutics Pipeline Market H1 2015 Research Report Available at RnRMarketResearch.com
PRWeb - Thu Feb 05, 7:31AM CST
The report "Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease). Coronary artery disease (Ischemic Heart Disease) is the most common type of heart disease. Coronary artery disease is the tightening or blockage of the coronary arteries. A severe adequate blockage may cause a heart attack. Coronary artery disease (Ischemic Heart Disease) is the foremost cause of death in US, UK and globally. Most ischaemic heart disease is caused by atherosclerosis. However there are a number of risk factors.
CRME: 9.76 (-0.14), GILD: 101.90 (+1.10), PSTI: 2.91 (+0.01), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), EGRX: 20.98 (+1.45), BMY: 60.04 (+0.56), RGDO: 1.17 (+0.02)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 11:47AM CST
SD: 2.09 (+0.14), RAVE: 13.57 (+0.28), SPPR: 1.63 (-0.17), PSTI: 2.91 (+0.01), ONTX: 2.27 (-0.02), LMNX: 15.45 (+0.02), NBG: 1.61 (+0.18), ARDX: 17.14 (+0.71), CSIQ: 28.84 (-0.30), LFVN: 1.11 (-0.02), XNPT: 6.69 (-0.21), GBR: 1.48 (-0.10), GENE: 8.04 (+1.90), RCII: 30.49 (+0.92), PWE: 2.45 (+0.02), PSTR: 4.63 (+0.14), SSYS: 67.16 (-0.34), ODP: 9.59 (-0.02), ENRJ: 2.81 (+0.06)
Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure
M2 - Tue Feb 03, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/lb556t/regenerative) has announced the addition of the "Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure" report to their offering. Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets, approaches and biology are discovered. Improved health care, nutrition and preventive medicine in the last few decades have all helped in increasing life expectancy WW. However, this has not translated in any reduction in the incidences or prevalence of chronic or critical illnesses! On the contrary, the incidence of chronic diseases like diabetes, obesity, arthritis etc. as well as cancer and the maladies associated with aging (dementia, Alzheimer's etc.) are on the rise. Consequently the pharma industry continues to grow and is projected to achieve sales in excess of the trillion dollar mark by 2020. By the next decade, one field which is poised to bring a paradigm change in the way diseases are treated is the Stem cell therapy/Regenerative Medicine space. The number of companies and products in the clinic has reached a critical mass, warranting a close watch by those interested in keeping pace with the development of new medicines. This report describes the key growth drivers and reasons for why this sector is poised for the "golden dawn" and forecasts that in the coming years, the translation of stem cell research to the clinic and market and Stem Cell Technologies Will Begin to Break Through by 2017. Key Topics Covered: 1. Executive summary 2. Introduction 3. Tough Choice- Autologous vs. Allogenic " Therapies 4. Regulatory Scenario 5. Marketed Cell based/Stem Cell Products 6. Progress and Challenges 7. Merger and Acquisition- Gaining Momentum in Regenerative Space 8. Progress in Specific Therapy Areas Companies Mentioned - CESCA Therapeutics Inc. [KOOL] - JCR Pharmaceuticals [4552:JP] - Japan Tissue Engineering Co., Ltd [7774:JP] - Medipost Co. Ltd [078160:KS] - Mesoblast Ltd [MSB:AU] - OCATA Therapeutics Inc. [OCAT] - Orgenesis [ORGS] - Pluristem Therapeutics Inc [PSTI:IT] - TiGenix NV [ TIG:BB] For more information visit http://www.researchandmarkets.com/research/lb...generative
KOOL: 0.88 (-0.14), PSTI: 2.91 (+0.01)
Market Maker Surveillance Report. TBIO, PSTI, STRI, DWTI, HART, ARDX, Losing Stocks With Lowest Price Friction For Monday, February 2nd 2015
M2 - Tue Feb 03, 3:14AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 5214 companies with "abnormal" market making, 3994 companies with positive Friction Factors and 2396 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Monday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Transgenomic Inc (OTC:TBIO), Pluristem Therapeutics Inc (NASDAQ
STI), STR Holdings Inc New (NYSE:STRI), (NYSE WTI), (NASDAQ:HART), (NASDAQ:ARDX). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . PSTI: 2.91 (+0.01), TBIO: 2.91 (+0.01), HART: 2.92 (+0.34), ARDX: 17.14 (+0.71), STRI: 1.65 (+0.04), DWTI: 95.90 (-7.40)
Pluristem Therapeutics: A Biotech Scam Promoted By A Bucket Shop
Probio Invest - at Seeking Alpha - Mon Feb 02, 3:37PM CST
CVM: 0.84 (-0.01), PSTI: 2.91 (+0.01), ORMP: 4.58 (+0.16)
Pluristem reports results from 20-patient study
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 9:54AM CST
PSTI: 2.91 (+0.01)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 8:12AM CST
BGMD: 0.88 (unch), SD: 2.09 (+0.14), FRO: 2.96 (+0.07), CAMT: 3.08 (+0.09), PWE: 2.45 (+0.02), HIHO: 3.30 (-0.17), PSTI: 2.91 (+0.01), ZGNX: 1.43 (+0.05), NBG: 1.61 (+0.18), SDRL: 12.32 (-0.70), GURE: 1.64 (-0.04)
Pluristem price-stoking analyst report questioned
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 6:37AM CST
PSTI: 2.91 (+0.01)
Pluristem Announces Significant New Finding From Its Phase I/II Muscle Injury Trial and Excellent Safety Profile for PLX-PAD Cells at Twelve Months
GlobeNewswire - Mon Feb 02, 1:45AM CST
Pluristem Therapeutics Inc. (Nasdaq
STI) (TASE STI), a leading developer of placenta-based cell therapies, announced an important new finding from its Phase I/II clinical trial of PLacental eXpanded (PLX-PAD) cells in the treatment of muscle injury after total hip arthroplasty (THA). Data showed that six months after surgery the magnitude of improvement in muscle force of the contralateral (non-operated) gluteal muscle was approximately 40 times larger in patients treated with 150 million PLX-PAD cells than in those who received placebo, and the difference was statistically significant (19.4 vs 0.5 Nm, p=0.0114). Patients treated with 300 million PLX-PAD cells also showed a larger increase in muscle force than patients injected with placebo (9.48 vs 0.46 Nm, p=0.227). Pluristem further announced positive twelve-month safety data from the trial. These findings follow the January 21, 2014 announcement that the study had met its primary efficacy and safety endpoints. The primary efficacy finding was the change in maximal voluntary isometric contraction force of the gluteal muscle in the operated leg at six months after total hip replacement. There was a large and statistically significant improvement in patients who were injected with 150 million cells versus those who received placebo (31.1 vs 5.4 Nm, p=0.0067). PSTI: 2.91 (+0.01)
Nasdaq stocks posting largest volume increases
AP - Thu Jan 29, 5:14PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
BELFB: 23.44 (+0.60), BELFA: 19.90 (-0.40), PSTI: 2.91 (+0.01), APPY: 0.45 (-0.01), NVC.TO: 11.27 (-0.23), GEVO: 0.23 (+0.03), PSTB: 6.94 (+0.04), OVLY: 10.65 (-0.05), PFMT: 6.02 (-0.02), BWINB: 23.41 (+0.01), AMIC: 10.75 (-0.10), APRI: 1.84 (-0.08), BWINA: 23.45 (-0.79), INOD: 2.78 (-0.02), XNCR: 15.47 (-0.22), FBSS: 17.59 (-0.11), NVCN: 9.08 (-0.17)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 8:12AM CST
CRMD: 3.27 (+0.02), FRO: 2.96 (+0.07), PSTI: 2.91 (+0.01), SILC: 46.99 (+0.90), VVUS: 2.68 (+0.13), NBG: 1.61 (+0.18), APPY: 0.45 (-0.01), CLB: 112.18 (+3.65), YHOO: 44.42 (+0.50), RCL: 75.56 (-1.19), COH: 39.85 (+0.64), QCOM: 70.88 (+0.49), IRE: 14.54 (+0.81), VGGL: 1.77 (-0.08), KATE: 33.89 (+0.05), XNCR: 15.47 (-0.22), MLNX: 46.35 (+1.47), FTNT: 33.23 (+0.25), BABA: 89.05 (+1.95)
Pluristem Therapeutics (PSTI) in Focus: Stock Surges 20.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 7:37AM CST
Pluristem Therapeutics, Inc. (PSTI) was a big mover last session, as the company saw its shares rise more than 20% on the day.
PSTI: 2.91 (+0.01), ALXN: 182.29 (+6.02)
Pluristem surges on bullish research report
Seeking Alpha - at Seeking Alpha - Wed Jan 28, 8:02AM CST
PSTI: 2.91 (+0.01)
Updated Coverage Report Focuses on Pluristem Therapeutics
Marketwired - Tue Jan 27, 3:00AM CST
Pluristem Therapuetics (NASDAQ: PSTI) is the subject of an updated coverage report by Acceleron Equity Research, a stock market research firm focused on emerging companies and technologies.
PSTI: 2.91 (+0.01)
